li001

RECITE Trial Shows Romiplostim Helps GI Cancer Patients Stay on Full-Dose Chemotherapy

Treatment /

The Phase 3 RECITE trial found that romiplostim can help gastrointestinal cancer patients stay on full-dose chemotherapy by preventing chemotherapy-induced thrombocytopenia (CIT), a condition marked by dangerously low platelet counts. The international study included 165 patients, most with stage 4 colorectal cancer receiving oxaliplatin-based chemotherapy. Researchers reported that 84% of patients treated with romiplostim avoided […]

RECITE Trial Shows Romiplostim Helps GI Cancer Patients Stay on Full-Dose Chemotherapy Read More »

CHMP Backs Camizestrant for ESR1-Mutated Advanced Breast Cancer

Drug Approvals /

The European Medicines Agency’s CHMP has recommended approval of camizestrant combined with a CDK4/6 inhibitor for patients with ER-positive, HER2-negative advanced breast cancer who develop ESR1 mutations before disease progression. The recommendation is based on results from the Phase 3 SERENA-6 trial, which used regular liquid biopsies to detect ESR1 mutations early. Patients who switched

CHMP Backs Camizestrant for ESR1-Mutated Advanced Breast Cancer Read More »

Study Identifies TLR2 as Key Driver of Immunotherapy Resistance in Pancreatic Cancer

Research Advances /

A new study has identified Toll-Like Receptor 2 (TLR2) as a major driver of immune resistance in pancreatic ductal adenocarcinoma (PDAC), one of the deadliest forms of cancer. Researchers found that TLR2 prevents cancer-fighting T cells from entering tumors, helping explain why pancreatic cancer often resists immunotherapy. Using mouse models and human tumor data, scientists

Study Identifies TLR2 as Key Driver of Immunotherapy Resistance in Pancreatic Cancer Read More »

Imetelstat Nearly Doubles Survival in High-Risk Myelofibrosis

Treatment /

An updated analysis showed that the telomerase inhibitor Imetelstat significantly improves survival in patients with high-risk myelofibrosis whose disease relapsed or became resistant after JAK inhibitor treatment. Researchers compared 59 IMbark patients with a matched real-world group of 54 patients treated before 2016. After nearly four years of follow-up, median overall survival reached 30.7 months

Imetelstat Nearly Doubles Survival in High-Risk Myelofibrosis Read More »

FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer

Drug Approvals /

The FDA has approved Datroway (datopotamab deruxtecan-dlnk, Dato-DXd) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval is based on results from the phase 3 TROPION-Breast02 trial. Dato-DXd significantly improved outcomes compared with standard chemotherapy. Median overall survival reached 23.7 months versus 18.7 months

FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer Read More »

GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in Large Real-World Study

Research Advances /

A real-world study suggests that GLP-1 receptor agonists, including semaglutide, may significantly reduce the risk of cancer metastasis in patients with early-stage solid tumors. Researchers analyzed data from over 10,000 patients with stage I–III cancers and compared those taking GLP-1 drugs with matched patients using DPP-4 inhibitors. Results showed a 31% to 50% reduction in

GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in Large Real-World Study Read More »

Breakthrough Advances in Targeted Therapy Reshape Lung Cancer Treatment Landscape

Targeted Therapy /

New studies highlight major progress in non-small cell lung cancer (NSCLC) treatment, particularly with targeted therapies and antibody-drug conjugates. The combination of amivantamab and lazertinib achieved a median overall survival of 41 months in treatment-naive patients with atypical EGFR-mutated NSCLC. Pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, showed a 70% response rate and 100%

Breakthrough Advances in Targeted Therapy Reshape Lung Cancer Treatment Landscape Read More »

Biomarker-Guided HER2/CD47 Therapy Shows Durable Responses After Enhertu Failure

Clinical Trails /

A phase 1b/2 trial showed promising results for a new combination therapy in patients with HER2-positive metastatic breast cancer who had already failed treatment with Enhertu. The study evaluated zanidatamab-hrii, a HER2-targeted bispecific antibody, together with evorpacept, a CD47 blocker, in 24 heavily pretreated patients. Overall, the response rate was 33.3%, but patients with centrally

Biomarker-Guided HER2/CD47 Therapy Shows Durable Responses After Enhertu Failure Read More »

mRNA-Lipid Nanoparticle Cancer Therapies Show Promise in Early Clinical Development

Research Advances /

mRNA-based cancer therapies work by delivering genetic instructions that tell cells to produce specific proteins without changing DNA, reducing risks linked to genome integration. However, mRNA is unstable and difficult to deliver into cells because it degrades quickly and cannot easily cross cell membranes. To overcome this, scientists use lipid nanoparticles (LNPs) that protect mRNA

mRNA-Lipid Nanoparticle Cancer Therapies Show Promise in Early Clinical Development Read More »

Adjuvant Pembrolizumab Reduces Recurrence and Mortality Risk in High-Risk Clear Cell Renal Cell Carcinoma After Surgery

Treatment /

A roundtable discussion led by Thomas Hutson highlighted the growing role of adjuvant Pembrolizumab in high-risk clear cell renal cell carcinoma (ccRCC) following nephrectomy, based on results from the phase 3 KEYNOTE-564 trial. The study compared one year of pembrolizumab versus placebo in patients with resected high-risk disease and showed a 29% reduction in recurrence

Adjuvant Pembrolizumab Reduces Recurrence and Mortality Risk in High-Risk Clear Cell Renal Cell Carcinoma After Surgery Read More »